Literature DB >> 2843282

Enhanced fibronectin receptor expression in Rous sarcoma virus-induced tumors.

S Saga1, W T Chen, K M Yamada.   

Abstract

The mechanisms by which cells acquire the capacity to invade interstitial connective tissues during malignancy are as yet uncertain. Since the fibronectin receptor complex has been implicated in transient, developmentally regulated steps of migration and morphogenesis in embryogenesis, we examined whether this receptor might be reexpressed at elevated levels in tumors. Immunofluorescence revealed increased expression of the receptor throughout frozen sections of Rous sarcoma virus-induced tumors in chickens, and expression was enhanced 4.7-fold after such malignant transformation of fibrocytes in vivo. Frozen thin sections showed that the increased antigen was localized diffusely in the plasma membrane. Western immunoblotting with monoclonal antibodies and immunoprecipitation analyses indicated that the tumor cell receptor contained all three known avian receptor subunits, i.e., Bands 1, 2, and 3. This type of induction of a key extracellular matrix receptor involved in cell migration may be a prerequisite for tumor cell invasion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843282

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Modulation of arachidonic acid metabolism by Rous sarcoma virus.

Authors:  K Barker; A Aderem; H Hanafusa
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma.

Authors:  S Nishimura; Y S Chung; M Yashiro; T Inoue; M Sowa
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

3.  Localization of integrin receptors for fibronectin, collagen, and laminin in human skin. Variable expression in basal and squamous cell carcinomas.

Authors:  J Peltonen; H Larjava; S Jaakkola; H Gralnick; S K Akiyama; S S Yamada; K M Yamada; J Uitto
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Distribution of VLA integrins in solid tumors. Emergence of tumor-type-related expression. Patterns in carcinomas and sarcomas.

Authors:  M Miettinen; R Castello; E Wayner; R Schwarting
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

5.  Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases.

Authors:  M J Demeure; C H Damsky; F Elfman; P E Goretzki; M G Wong; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

6.  Biosynthesis, surface expression and function of the fibronectin receptor after rat liver cell transformation to tumorigenicity.

Authors:  M Decastel; M A Doyennette-Moyne; E Gouet; M Aubery; P Codogno
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

Review 7.  Fibronectin and integrins in invasion and metastasis.

Authors:  S K Akiyama; K Olden; K M Yamada
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

8.  Integrin distributions in renal cell carcinomas of various grades of malignancy.

Authors:  M Korhonen; L Laitinen; J Ylänne; G K Koukoulis; V Quaranta; H Juusela; V E Gould; I Virtanen
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  Plasticity of integrin expression by nerve-derived connective tissue cells. Human Schwann cells, perineurial cells, and fibroblasts express markedly different patterns of beta 1 integrins during nerve development, neoplasia, and in vitro.

Authors:  L L Hsiao; J Peltonen; S Jaakkola; H Gralnick; J Uitto
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.

Authors:  S K Akiyama; S S Yamada; W T Chen; K M Yamada
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.